Tesofensine - Saniona

Drug Profile

Tesofensine - Saniona

Alternative Names: NS-2330; Tesofensine

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NeuroSearch
  • Developer Medix; Saniona
  • Class Antidementias; Antiparkinsonians; Chlorobenzenes; Heterocyclic bicyclo compounds; Neuroprotectants; Nootropics; Obesity therapies; Small molecules
  • Mechanism of Action Biogenic monoamine uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Obesity
  • Discontinued Alzheimer's disease; Parkinson's disease

Most Recent Events

  • 21 Aug 2017 Phase-III clinical trials in Obesity in Mexico (PO)
  • 12 Apr 2017 Medix receives regulatory approval for phase III trial of ATIR 101 in Mexico
  • 21 Dec 2016 Medix files a clinical trial application for tesofensine in Mexico
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top